Literature DB >> 25174325

The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research.

Matthew J Resnick1, Daniel A Barocas2, Alicia K Morgans3, Sharon E Phillips4, Tatsuki Koyama4, Peter C Albertsen5, Matthew R Cooperberg6, Michael Goodman7, Sheldon Greenfield8, Ann S Hamilton9, Karen E Hoffman10, Richard M Hoffman11, Sherrie H Kaplan8, Dan McCollum12, Lisa E Paddock13, Janet L Stanford14, Antoinette M Stroup13, Xiao-Cheng Wu15, David F Penson16.   

Abstract

BACKGROUND: Despite the paramount importance of patient-reported outcomes, little is known about the evolution of patient-reported urinary and sexual function over time.
OBJECTIVE: To evaluate differences in pretreatment urinary and sexual function in two population-based cohorts of men with prostate cancer enrolled nearly 20 yr apart. DESIGN, SETTING, AND PARTICIPANTS: Patients were enrolled in the Prostate Cancer Outcomes Study (PCOS) or the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study, two population-based cohorts that enrolled patients with incident prostate cancer from 1994 to 1995 and from 2011 to 2012, respectively. Participants completed surveys at baseline and various time points thereafter. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We performed multivariable logistic and linear regression analysis to investigate differences in pretreatment function between studies. RESULTS AND LIMITATIONS: The study comprised 5469 men of whom 2334 (43%) were enrolled in PCOS and 3135 (57%) were enrolled in CEASAR. Self-reported urinary incontinence was higher in CEASAR compared with PCOS (7.7% vs 4.7%; adjusted odds ratio [OR]: 1.83; 95% confidence interval [CI], 1.39-2.43). Similarly, self-reported erectile dysfunction was more common among CEASAR participants (44.7% vs 24.0%) with an adjusted OR of 3.12 (95% CI, 2.68-3.64). Multivariable linear regression models revealed less favorable self-reported baseline function among CEASAR participants in the urinary incontinence and sexual function domains. The study is limited by its observational design and possibility of unmeasured confounding.
CONCLUSIONS: Reporting of pretreatment urinary incontinence and erectile dysfunction has increased over the past two decades. These findings may reflect sociological changes including heightened media attention and direct-to-consumer marketing, among other potential explanations. PATIENT
SUMMARY: Patient reporting of urinary and sexual function has evolved and is likely contingent on continually changing societal norms. Recognizing the evolving nature of patient reporting is essential in efforts to conduct high-quality, impactful comparative effectiveness research.
Copyright © 2014 European Association of Urology. All rights reserved.

Entities:  

Keywords:  Patient-reported outcomes; Prostate cancer; Quality of life; Sexual function; Urinary function

Mesh:

Year:  2014        PMID: 25174325      PMCID: PMC4412750          DOI: 10.1016/j.eururo.2014.08.035

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  29 in total

1.  For and against: Direct to consumer advertising is medicalising normal human experience: For.

Authors:  Barbara Mintzes
Journal:  BMJ       Date:  2002-04-13

2.  For and against: Direct to consumer advertising is medicalising normal human experience: Against.

Authors:  Silvia N Bonaccorso; Jeffrey L Sturchio
Journal:  BMJ       Date:  2002-04-13

3.  Direct-to-consumer advertising--strengthening our health care system.

Authors:  Alan F Holmer
Journal:  N Engl J Med       Date:  2002-02-14       Impact factor: 91.245

4.  Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression.

Authors:  Julie M Donohue; Ernst R Berndt; Meredith Rosenthal; Arnold M Epstein; Richard G Frank
Journal:  Med Care       Date:  2004-12       Impact factor: 2.983

5.  Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy.

Authors:  Arnold L Potosky; Bryce B Reeve; Limin X Clegg; Richard M Hoffman; Robert A Stephenson; Peter C Albertsen; Frank D Gilliland; Janet L Stanford
Journal:  J Natl Cancer Inst       Date:  2002-03-20       Impact factor: 13.506

6.  Stigma as a barrier to recovery: Perceived stigma and patient-rated severity of illness as predictors of antidepressant drug adherence.

Authors:  J A Sirey; M L Bruce; G S Alexopoulos; D A Perlick; S J Friedman; B S Meyers
Journal:  Psychiatr Serv       Date:  2001-12       Impact factor: 3.084

7.  Validation study of retrospective recall of disease-targeted function: results from the prostate cancer outcomes study.

Authors:  J Legler; A L Potosky; F D Gilliland; J W Eley; J L Stanford
Journal:  Med Care       Date:  2000-08       Impact factor: 2.983

8.  Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study.

Authors:  A L Potosky; L C Harlan; J L Stanford; F D Gilliland; A S Hamilton; P C Albertsen; J W Eley; J M Liff; D Deapen; R A Stephenson; J Legler; C E Ferrans; J A Talcott; M S Litwin
Journal:  J Natl Cancer Inst       Date:  1999-10-20       Impact factor: 13.506

9.  Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study.

Authors:  A L Potosky; J Legler; P C Albertsen; J L Stanford; F D Gilliland; A S Hamilton; J W Eley; R A Stephenson; L C Harlan
Journal:  J Natl Cancer Inst       Date:  2000-10-04       Impact factor: 13.506

10.  The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure.

Authors:  M S Litwin; R D Hays; A Fink; P A Ganz; B Leake; R H Brook
Journal:  Med Care       Date:  1998-07       Impact factor: 2.983

View more
  5 in total

1.  The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples.

Authors:  Brock O'Neil; Tatsuki Koyama; JoAnn Alvarez; Ralph M Conwill; Peter C Albertsen; Matthew R Cooperberg; Michael Goodman; Sheldon Greenfield; Ann S Hamilton; Karen E Hoffman; Richard M Hoffman; Sherrie H Kaplan; Janet L Stanford; Antoinette M Stroup; Lisa E Paddock; Xiao-Cheng Wu; Robert A Stephenson; Matthew J Resnick; Daniel A Barocas; David F Penson
Journal:  J Urol       Date:  2015-09-03       Impact factor: 7.450

2.  Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.

Authors:  Athene Lane; Chris Metcalfe; Grace J Young; Tim J Peters; Jane Blazeby; Kerry N L Avery; Daniel Dedman; Liz Down; Malcolm D Mason; David E Neal; Freddie C Hamdy; Jenny L Donovan
Journal:  BJU Int       Date:  2016-08-17       Impact factor: 5.588

3.  Erectile dysfunction and quality of life in men receiving methadone or buprenorphine maintenance treatment. A cross-sectional multicentre study.

Authors:  Fabio Lugoboni; Lorenzo Zamboni; Angela Federico; Stefano Tamburin
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

4.  Cohort profile: the Martinique Cancer Registry and the quality of life prostate cancer cohort (QoL Prostate-MQ): challenges and prospects for reducing disparities in the Caribbean.

Authors:  Clarisse Joachim; Jacqueline Veronique-Baudin; Thierry Almont; Stephen Ulric-Gervaise; Jonathan Macni; Olivier Pierre-Louis; Lidvine Godaert; Moustapha Drame; Jean-Luc Novella; Karim Farid; Vincent Vinh-Hung; Patrick Escarmant
Journal:  BMJ Open       Date:  2018-07-25       Impact factor: 2.692

5.  Determinants of self-reported functional status (EPIC-26) in prostate cancer patients prior to treatment.

Authors:  Rebecca Roth; Sebastian Dieng; Alisa Oesterle; Günter Feick; Günther Carl; Andreas Hinkel; Thomas Steiner; Björn Theodor Kaftan; Frank Kunath; Boris Hadaschik; Simba-Joshua Oostdam; Rein Jüri Palisaar; Mateusz Koralewski; Burkhard Beyer; Björn Haben; Igor Tsaur; Simone Wesselmann; Christoph Kowalski
Journal:  World J Urol       Date:  2020-02-10       Impact factor: 4.226

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.